Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167582 | 0.83 | TDP1 (0.47) | MAPK1 | |
| SCHEMBL23733048 | 0.81 | MAOB (0.46) | — | |
| SCHEMBL13654080 | 0.81 | KMT2A (0.58) | — | |
| SCHEMBL9055584 | 0.80 | CYP2C9 (0.55) | MAPK1CYP2C9CYP2C19 | |
| SCHEMBL13654172 | 0.80 | POLB (0.43) | MAPK1 | |
| SCHEMBL13659077 | 0.79 | TP53 (0.36) | CYP3A4MAPK1EGFRCYP2C9CYP2C19 | |
| SCHEMBL13538700 | 0.79 | KDM4E (0.50) | MAPK1 | |
| SCHEMBL4104850 | 0.78 | CCNT1 (0.44) | CYP3A4 | |
| SCHEMBL20582500 | 0.78 | CYP3A4 (0.46) | CHRNB2CHRNA4CYP3A4CHRNB4CHRNA3 | |
| SCHEMBL13654559 | 0.77 | KMT2A (0.42) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| CN-101410120-A | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES INC (US) | 2009-04-15 | — | — | CN | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | CHRNB2 4688/4885CHRNA4 4415/4885CYP3A4 1894/4885 |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | PHOSPHO1, TNF, PTGES | CHRNB2 4688/4885CHRNA4 4415/4885CYP3A4 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.